Demographic and Clinical Characteristics of Patients
| Patient no. | Months from diagnosis | Primary | Surgery | Tumor burden | Ki-67 | Earlier treatment | Ongoing treatment | Body mass index | Hormones |
| 1 (F, 67 y) | 8 | Pancreas | Ileocecal resection (ileus) | Pancreas, liver | 3% | — | STZ + 5-FU, lanreotide,* SD | 18.9 (50 kg) | CgA 62, Glu 214, Ins 171 |
| 2 (M, 53 y) | 72 | Lung, pancreas | Pancreas | Pancreas, lung, liver | 11% | — | — | 22.2 (70 kg) | — |
| 3 (F, 73 y) | 36 | Pancreas | — | Pancreas, liver | 31% | STZ + 5-FU | Octreotide acetate, long-acting* | 26.1 (71 kg) | CgA 9.1 |
| 4 (M, 67 y) | 72 | Small intestine | Small-intestine resection | Liver, LN, paraaortal | <1% | — | IFN-α + octreotide acetate, long-acting,* SD | 23.6 (79 kg) | CgA 20, U-5HIAA 31 |
| 5 (M, 58 y) | 5 | Small intestine | — | Primary liver, LN, mesentery, paraaortal | 2%–3% | — | — | 24.8 (75 kg) | CgA 1,640, U-5HIAA 2,457 |
| 6 (F, 63 y) | 3 | Small intestine | — | Primary liver, LN, abd, bone | <1% | — | — | 22.3 (58.6 kg) | CgA 406, U-5HIAA 285 |
| 7 (M, 50 y) | 2 | Small intestine | Small intestine, LN, mesentery, omentum | Liver, LN, abd, mediastinum | 12%–18% | — | Octreotide acetate, long-acting* | 23.3 (85.1 kg) | CgA 8.2, U-5-HIAA 100 |
| 8 (M, 65 y) | 48 | Pancreas | — | Pancreas, liver | 25%–30% | Carbo-VP 16, TMZ/Cap | TMZ + bevacizumab, SD | 24.6 (71 kg) | CgA 20, PP 280 |
| 9 (F, 75 y) | 22 | Lung | Left pulmectomy | Liver | — | — | 33 (80.5 kg) | CgA 7.2 | |
| 10 (M, 44 y) | 5 | Small intestine | Small-intestine resection | Mesentary, peritoneum | 10% | — | — | 36 (120.5 kg) | CgA 6.0 |
↵* Stopped 4 wk before PET examination.
STZ = streptozotocin; 5-FU = 5-fluorouracil; SD = stable disease; CgA = chromogranin A (nmol/L); Glu = glucagon (ng/L); Ins = insulin (mE/L); LN = lymph node; IFN-α = interferon alpha; U-5HIAA = urinary 5-hydroxyindoleacetic acid (μmol/d); abd = abdomen; carbo = carboplatin; VP 16 = etoposide; TMZ = temozolomide; Cap = capecitabine; PP = pancreatic polypeptide (pmol/L).